Trastuzumab Emtansine: A Review of Its Use in Patients with HER2-Positive Advanced Breast Cancer Previously Treated with Trastuzumab-Based Therapy-Reference-Cited by-同舟云学术

Trastuzumab Emtansine: A Review of Its Use in Patients with HER2-Positive Advanced Breast Cancer Previously Treated with Trastuzumab-Based Therapy

Published:2014-03-22 Issue:6 Volume:74 Page:675-686
ISSN:0012-6667
Container-title:Drugs
language:en
Short-container-title:Drugs

Author:

Dhillon Sohita

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical)

Link

http://link.springer.com/content/pdf/10.1007/s40265-014-0201-0.pdf

Reference56 articles.

1. World Health Organization. Breast cancer: prevention and control. 2014. http://www.who.int/cancer/detection/breastcancer/en/index1.html . Accessed 4 Mar 2014.

2. Ross JS, Slodkowska EA, Symmans WF, et al. The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine. Oncologist. 2009;14(4):320–68.

3. Hurvitz SA, Kakkar R. The potential for trastuzumab emtansine in human epidermal growth factor receptor 2 positive metastatic breast cancer: latest evidence and ongoing studies. Ther Adv Med Oncol. 2012;4(5):235–45.

4. Burris HA 3rd, Tibbitts J, Holden SN, et al. Trastuzumab emtansine (T-DM1): a novel agent for targeting HER2+ breast cancer. Clin Breast Cancer. 2011;11(5):275–82.

5. Genentech Inc. Kadcyla™ (ado-trastuzumab emtansine): US prescribing information. 2013. http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/125427s012lbl.pdf . Accessed 4 Mar 2014.

Cited by 34 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Generation of a Novel SORT1×HER2 Bispecific Antibody–Drug Conjugate Targeting HER2-Low-Expression Tumor;International Journal of Molecular Sciences;2023-11-07

2. The Evolving Landscape of Antibody–Drug Conjugates: In Depth Analysis of Recent Research Progress;Bioconjugate Chemistry;2023-10-11

3. A Review of Margetuximab-Based Therapies in Patients with HER2-Positive Metastatic Breast Cancer;Cancers;2022-12-21

4. Breaking the Bottleneck in Anticancer Drug Development: Efficient Utilization of Synthetic Biology;Molecules;2022-11-02

5. Pharmacological profile - trastuzumab emtansine;Onkologie;2022-09-29